Storage mite allergen extracts

PreclinicalBiologic

HHaukeland University Hospital

Storage mite allergen extracts is one of 27 biologic programs targeting Rhinitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RhinitisActive, not recruiting

RhinitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Rhinitis

#DrugCompanyPhaseTrials

Flovent

GSK

Approved

1 2

Prevacid

Takeda

Approved

1 3

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

4 4

Singulair

OOrganon and Co

Approved

1 5

Rhofade

KKenvue Brands

Approved

1 6

Xyzal

CChattem

Approved

1 7

Immunotherapy

Bristol-Myers Squibb

Approved

1 8

Diluent

Sanofi

Approved

1 9

Veramyst

GSK

Phase 3

1 10

Pulmicort

SSalix

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rhinitis1 trial

Nasal Provocation Testing in Occupational Rhinitis

Completed·HHaukeland University Hospital·N/A·NCT01436851·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Storage mite allergen extracts. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Storage mite allergen extracts compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Storage mite allergen extracts. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haukeland University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: HHaukeland University Hospital

Storage mite allergen extracts

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rhinitis1 trial

References

Drug Info

Quick Facts

Related News